Developing a clinical grade human adipose decellularized biomaterial

Daniel J Hayes; Jeffrey M Gimble

doi:10.1016/j.bbiosy.2022.100053

Developing a clinical grade human adipose decellularized biomaterial

Biomater Biosyst. 2022 May 25:7:100053. doi: 10.1016/j.bbiosy.2022.100053. eCollection 2022 Aug.

Authors

Daniel J Hayes¹, Jeffrey M Gimble²

Affiliations

¹ Department of Biomedical Engineering, Pennsylvania State University, State College, PA, USA.
² Obatala Sciences Inc., New Orleans, LA, USA.

Abstract

While tissue engineering investigators have appreciated adipose tissue as a repository of stromal/stem cells, they are only now beginning to see its value as a decellularized tissue resource. Independent academic investigators have successfully extracted lipid, genomic DNA and proteins from human fat to create a decellularized extracellular matrix enriched in collagen, glycoproteins, and proteoglycans. Pre-clinical studies have validated its compatibility with stromal/stem cells and its ability to support adipogenesis in vitro and in vivo in both small (murine) and large (porcine) subcutaneous implant models. Furthermore, Phase I safety clinical trials have injected decellularized human adipose tissue scaffolds in human volunteers without incident for periods of up to 127 days. This commentary takes an opinionated look at the under-appreciated but potential benefits of obesity as an increasingly available biomaterial resource.

Keywords: ASC, Adipose stromal/stem cell; Adipose; Biomaterial; CD4, Cluster of differentiation 4; ECM, Extracellular matrix; M2, alternatively activated macrophage; MTF, Musculoskeletal Transplant Foundation; Scaffold; Stromal/Stem Cell.